414 related articles for article (PubMed ID: 33375286)
1. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives.
Birzu C; French P; Caccese M; Cerretti G; Idbaih A; Zagonel V; Lombardi G
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375286
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study.
Lombardi G; Caccese M; Padovan M; Cerretti G; Pintacuda G; Manara R; Di Sarra F; Zagonel V
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572958
[TBL] [Abstract][Full Text] [Related]
4. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
5. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
Farrell C; Shi W; Bodman A; Olson JJ
J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.
Franceschi E; Minichillo S; Brandes AA
CNS Drugs; 2017 Aug; 31(8):675-684. PubMed ID: 28681349
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Zeyen T; Potthoff AL; Nemeth R; Heiland DH; Burger MC; Steinbach JP; Hau P; Tabatabai G; Glas M; Schlegel U; Grauer O; Krex D; Schnell O; Goldbrunner R; Sabel M; Thon N; Delev D; Clusmann H; Seidel C; Güresir E; Schmid M; Schuss P; Giordano FA; Radbruch A; Becker A; Weller J; Schaub C; Vatter H; Schilling J; Winkler F; Herrlinger U; Schneider M
Trials; 2022 Jan; 23(1):57. PubMed ID: 35045869
[TBL] [Abstract][Full Text] [Related]
8. Current therapeutic options for glioblastoma and future perspectives.
Aquilanti E; Wen PY
Expert Opin Pharmacother; 2022 Oct; 23(14):1629-1640. PubMed ID: 36100970
[TBL] [Abstract][Full Text] [Related]
9. Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches.
McMahon DJ; Gleeson JP; O'Reilly S; Bambury RM
Med Oncol; 2022 Jun; 39(9):129. PubMed ID: 35716200
[TBL] [Abstract][Full Text] [Related]
10. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P
J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic options in recurrent glioblastoma--An update.
Seystahl K; Wick W; Weller M
Crit Rev Oncol Hematol; 2016 Mar; 99():389-408. PubMed ID: 26830009
[TBL] [Abstract][Full Text] [Related]
14. Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma.
Wang Y; Li S; Peng Y; Ma W; Wang Y; Li W
Cancer Innov; 2023 Apr; 2(2):114-130. PubMed ID: 38090060
[TBL] [Abstract][Full Text] [Related]
15. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
16. How did lomustine become standard of care in recurrent glioblastoma?
Weller M; Le Rhun E
Cancer Treat Rev; 2020 Jul; 87():102029. PubMed ID: 32408220
[TBL] [Abstract][Full Text] [Related]
17. Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials.
Chen W; Liu D; Liu P; Kong Z; Wang Y; Wang Y; Ma W
Chin J Cancer Res; 2021 Jun; 33(3):417-432. PubMed ID: 34321837
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
Thivat E; Casile M; Moreau J; Molnar I; Dufort S; Seddik K; Le Duc G; De Beaumont O; Loeffler M; Durando X; Biau J
BMC Cancer; 2023 Apr; 23(1):344. PubMed ID: 37060055
[TBL] [Abstract][Full Text] [Related]
19. [Targeted therapy in glioblastoma: update and perspectives].
Idbaih A; Duran-Peña A; Alentorn A
Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
[TBL] [Abstract][Full Text] [Related]
20. Current medical treatment of glioblastoma.
Venur VA; Peereboom DM; Ahluwalia MS
Cancer Treat Res; 2015; 163():103-15. PubMed ID: 25468228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
